Application of magnesium sulphate as a "multimodal general anesthesia" protocol in patients undergoing hysteroscopy: a randomized controlled study

Peng-fei Gao  
North Sichuan Medical College

Jing-yan Lin  
Affiliated Hospital of North Sichuan Medical College

Shun Wang  
North Sichuan Medical College

Yun-feng Zhang  
North Sichuan Medical College

Guo-qiang Wang  
North Sichuan Medical College

Qi Xu  
North Sichuan Medical College

Xiao Guo  
North Sichuan Medical College

Research article

Keywords: multimodal general anesthesia, magnesium sulphate, hysteroscopy, pain, opioid, monitored anesthesia care

Posted Date: June 19th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-26722/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on September 21st, 2020. See the published version at https://doi.org/10.1186/s12871-020-01158-9.
Abstract

**Background:** The purpose of the study was to applicate magnesium sulphate as a "multimodal general anesthesia" protocol to reduce perioperative opioids requirements in patients undergoing hysteroscopy.

**Methods:** 70 patients scheduled for hysteroscopy were randomly divided into 2 groups. Patients in Group M received intravenous magnesium sulfate 50 mg/kg in 100 ml of isotonic saline over 15 min before fentanyl injection and then 15 mg/kg per hour by continuous intravenous infusion. Patients in the control group received an equal volume of normal saline as placebo. All patients were anesthetized under a BIS guided monitored anesthesia care with propofol and fentanyl. Intraoperative hemodynamic variables were recorded and postoperative pain scores were assessed with verbal numerical rating scale (VNRS) 1 min, 15 min, 30 min, 1 hour, and 4 hours after recovery of consciousness. The primary outcome of our study was total amount of intraoperative and postoperative analgesics administered.

**Results:** Postoperative serum magnesium concentrations in Group C were significantly decreased than preoperative levels (0.86 ± 0.06 to 0.80 ± 0.08 mmol/L, P=0.001) while there was no statistical change in Group M (0.86 ± 0.07 to 0.89 ± 0.07 mmol/L, P=0.129). Bradycardia did not occur in either group and the incidence of hypotension was comparable between the two groups. Total dose of fentanyl given to patients in Group M was less than the one administered to Group C [100 (75-150) vs 145 (75-175) μg, median (range); P < 0.001]. Fewer patients in Group M required additional analgesics postoperatively. In addition, patients receiving magnesium displayed lower VNRS scores at 15 min, 30 min, 1 hour, and 4 hours postoperatively.

**Conclusions:** Intravenous infusion of magnesium sulphate significantly reduces postoperative pain and perioperative opioid requirements without increasing the risk of cardiovascular side effects. Meanwhile, it was beneficial to maintain a stable serum magnesium concentration after the procedure.

**Trial registration:** www.chictr.org.cn ChiCTR1900024596 date of registration: July 18th 2019.

**Background**

Hysteroscopy is currently one of the most common procedures for patients with cervical or endometrial disorders [1]. Although the development of new techniques and equipment has made hysteroscopy a minimally invasive procedure, it’s still believed to be a painful experience which need effective analgesia to achieve maximum patient comfort and cooperation [2,3]. Fentanyl is generally the preferred agent administered as analgesics during hysteroscopy because of its low prize and powerful analgesic effect. However, serious side effects such as respiratory depressant and postoperative nausea and vomiting (PONV) restrict its dosage in clinical practice.

Nowadays, the concept of “multimodal general anesthesia” has been proposed to use smaller dose of multiple agents and to target simultaneously multiple targets in the nociceptive system, avoid sole reliance on opioid, thereby increasing the antinociceptive effects and reducing each drug’s side effects [4].
When compared with opioid-free anaesthesia, strong evidence shows that opioid-inclusive anaesthesia does not reduce postoperative pain, but is associated with more PONV [5]. As the fourth most plentiful cation in the body, magnesium (Mg) acts as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and calcium channel blocker [6, 7]. It has antinociceptive stimulus property [7]. A recent study indicated that serum magnesium levels was significantly decreased after hysteroscopy [8] and magnesium deficiency produces hyperalgesia that can be reversed by NMDA antagonists [9]. In consequence, magnesium sulphate may be an alternative medicine to multimodal general anesthesia. To the best of our knowledge, there are scanty of clinical study evaluate the effect of magnesium sulphate on multimodal general anesthesia in hysteroscopy.

We hypothesis that intravenous magnesium sulphate administration during hysteroscopy as monitored by Bispectral Index Scale (BIS) could reduce intraoperative and postoperative analgesics requirements and their related side effects.

**Methods**

**Ethics and registration**

This randomized controlled study adheres to CONSORT guideline. The study was approved by the Ethics Committee of Affiliated Hospital of North Sichuan Medical College [2019ER(R) 074-01] and was registered at the Chinese Clinical Trials Registry (ChiCTR1900024596). Written informed consent was obtained from each patient.

**Patient inclusion and exclusion criteria**

A total of 70 consenting female patients aged 18-55 years old, with American Society of Anesthesiologists (ASA) physical status I or II, scheduled for hysteroscopy between July 2019 and October 2019 were enrolled in this randomized double-blind placebo-controlled clinical trial. Exclusion criteria were patients with cardiovascular disease (ejection fraction < 40%, atrioventricular conductance disturbance, hypertension, coronary heart disease, or cerebrovascular disease), liver dysfunction (transaminases above the normal level), renal failure (creatinine > 150 μmol/L), preoperative opioids use, neurological disorder, diabetes, morbid obesity (body mass index > 30 kg/m²), history of neuromuscular disease, history of chronic pain, drugs or alcohol abuse.

**Randomization and blinding**

Patients were randomly assigned into the control group (Group C, n=35) and the magnesium group (Group M, n=35) by computer-generated randomization Web-based, random number generator (available at http://www.random.org). Patients in the Group M received IV magnesium sulfate 50 mg/kg in 100 ml of isotonic saline over 15 min before fentanyl injection and then 15 mg/kg per hour by continuous IV infusion until the end of the procedure, whereas patients in the Group C received an equal volume of normal saline as a placebo. An anesthetic technician who did not participate in the study was provided
with group assignment and prepared the Infusions in pharmacy. Anesthesia provider, patients, and all investigators were blinded to group assignment until completion of the study.

**Anesthesia**

On arrival in the operating room, ECG, noninvasive blood pressure (NIBP), and pulse oximetry (SpO\textsubscript{2}) monitoring were commenced. Electrodes were placed on the forehead to monitor bispectral index (BIS).

After a 20-G intravenous cannula was inserted, 100 ml of study medicine was started to infusion. Four minutes before the start of procedure, all patients received 1.5 μg/kg bolus doses of fentanyl. Sedation was initiated with propofol 1.5 mg/kg and then maintained at a rate of 4-12 mg/kg per hour. The speed of propofol infusion was adjusted to maintain a BIS value of 50 to 60. Inadequate analgesia was defined as body movement or an increase in mean blood pressure (MBP) or heart rate (HR) by more than 15% of baseline [11]. A 0.5 μg/kg bolus dose of fentanyl was administered if signs of inadequate analgesia occurred with a BIS value in the recommended range contemporarily. When inadequate analgesia occurred and BIS value simultaneously increased upon 60 or even 70, the speed of propofol infusion was enhanced and a 0.5 μg/kg bolus dose of fentanyl was administered. The infusions of propofol and study medicine were ceased when gynecologists pronounced the completion of the procedure.

During the procedures, all patients were allowed to breathe spontaneously with oxygen 2 L/min via face mask. When SpO\textsubscript{2} < 95% were observed, patients were managed by jaw thrust and when SpO\textsubscript{2} < 90% by assisted ventilation. At the same time, ephedrine or atropine was administered if hypotension (SBP ≤ 90mmHg) or bradycardia (HR ≤ 45bmp) was observed.

**Data collection**

After the procedures, patients were transferred to the postanesthesia care unit (PACU) if modified Aldrete score ≥ 9. Respiratory depression (defined as SpO\textsubscript{2} less than 95% and 90%), time for recovery of consciousness (time between disconnection of propofol infusion and ability for the patient to provide her name) were recorded. Postoperative pain score was assessed with verbal numerical rating scale (VNRS; 0 = no pain; 4-6 = moderate pain; 10 = worst pain). The VNRS scores were recorded 1 min, 15 min, 30 min, 1 hour, and 4 hours after recovery of consciousness. If VNRS scores ≥ 4, bolus doses of rescue analgesics (dezocine 10 mg) were administered intravenously. Patients with PONV were treated with intravenous ondansetron (4 mg). Gynecologists and Patients’ global satisfaction levels regarding fluency of procedures or comfort level were assessed immediately and 4 h after procedures respectively using a satisfaction scale (0 = complete dissatisfaction; 10 = best satisfaction). Serum magnesium concentrations were collected one day before and one day after the procedure. In addition, PONV and other adverse effects were also recorded during the study period.

**Outcomes**

The primary outcome of our study was total amount of intraoperative and postoperative analgesics administered. The following data were collected as secondary outcomes of interest: serum magnesium
concentrations, duration of procedure, variations of HR and MBP during procedures, respiratory depression, time for recovery of consciousness, PONV, satisfaction score from gynecologists and patients, VNRS scores after procedures.

**Sample size and statistical analysis**

The sample size of this study was based on the total dose of fentanyl requirement. Sample size calculations based on 10 subjects per group were required to achieve a power of 90% with a type 1 error of 0.05. Preliminary data revealed that a total sample size of 62 was required (31 per group) to detect 0.5 μg/kg reduction in fentanyl requirement [12]. In consideration of possible dropout, we enrolled 35 subjects per group.

Data were analyzed using SPSS for Windows version 19.0 (SPSS Inc, Chicago, IL, USA). Normality assessment of distribution was performed with Kolmogorov-Smirnov or Shapiro-Wilk tests. Data were set out in the form of mean ± standard deviation, median (range), or the number of patients (proportion). The Student’s t-test was employed in the analysis of the parametric data. Nonparametric data were analyzed by using the Mann-Whitney U test. Categorical data were analyzed using Fisher’s exact test or the chi-square test, if appropriate. Two-way repeated measures ANOVA was used to compare HR and MBP at each point of time. A P-value of less than 0.05 was accepted as statistically significant.

**Results**

Flow diagram of the study was presented in Fig. 1: A total of 70 patients participated in our study without exclusion. They were randomly divided into two groups: the control group (Group C, n=35) and the magnesium group (Group M, n=35). One patient in Group C and two patients in Group M were lost to follow up, thus 34 patients in Group C and 33 patients in Group M were analyzed. The patients’ demographic characteristics and satisfaction scores are described in Table 1. Age, height, weight, BMI, and ASA physical status were statistically similar between the two groups. There were no significant differences in the duration of procedure and recovery of consciousness. Gynecologists showed higher satisfaction scores in Group M (P = 0.026) while patients displayed similar satisfaction scores between two groups (P = 0.057).

Preoperative serum magnesium concentrations were similar between the two groups (0.86 ± 0.06 vs 0.86 ± 0.07 mmol/L in Group C and Group M, respectively). Postoperative serum magnesium concentrations in Group C were significantly declined than preoperative levels (0.86 ± 0.06 to 0.80 ± 0.08 mmol/L, P=0.001) while there was no statistical change in Group M (0.86 ± 0.07 to 0.89 ± 0.07 mmol/L, P=0.129).

The total dose and number of times fentanyl given to patients in Group M was less than these administered to Group C [100 (75-150) vs 145 (75-175) μg, median (range); P<0.001], [2(1-4) vs 3(1-5), median (range); P<0.001], meanwhile, propofol consumption was similar between the two groups (P = 0.157). Thus, IV magnesium sulphate allowed a 31% reduction in the total dose of fentanyl used during the procedure (Table 2). In addition, fewer patients in Group M required additional analgesics (P = 0.036).
VNRS scores at 1 min after recovery of consciousness were statistically similar between the two groups but were statistically lower in the Group M at 15 min, 30 min, 1 hour, and 4 hours postoperatively than in Group C ($P < 0.05$, Table 3).

Hemodynamic variables during the procedure at each point of time are shown in Fig. 2. A similar trend of heart rate was observed in Group C and Group M, but it was significantly lower in Group M at 5 min, 10 min, 15 min after propofol administration, the end of the procedure, and arrive in PACU. ($P < 0.05$, Fig. 2 A). Mean blood pressures at 1 min and 5 min after propofol administration were significantly lower in Group M ($P < 0.05$, Fig. 2 B). Hypertension or bradycardia did not occur in either group. Incidence of hypotension was comparable between the two groups and patients were treated with ephedrine when hypotension was observed. However, there was no case of tachycardia in Group M, while two cases were observed in Group C (Table 2). The numbers of patients who experienced oxygen desaturation below 95% (18 vs 12 subjects in Group C and Group M, respectively) or below 90% (12 vs 7 subjects in Group C and Group M, respectively) were statistically insignificant between the two groups (Table 2). No patient experienced a serious adverse event related to the infusion of magnesium sulphate.

**Discussion**

In the present study, we evaluated the antinociceptive effects of intravenous magnesium sulphate by reducing perioperative analgesics requirements during hysteroscopy in patients under monitored anesthesia care. We demonstrate, in hysteroscopy, that adding intravenous magnesium sulphate to propofol-fentanyl anesthesia results in a reduction in intraoperative fentanyl and postoperative rescue analgesic needs. Patients receiving magnesium displayed lower heart rate and less postoperative pain.

Nowadays, hysteroscopic surgeries are frequently performed in ambulatory surgery settings, which benefit the patients for shorter hospital stays and reduction of costs [13]. This procedure has been considered a less invasive treatment, combine short operative time with early discharge, postoperative analgesia is always underestimated and ignored. However, severe pain is caused by uterine cervical dilatation and intrauterine tissue extraction, thus effective pain management is the key point for patients’ comfort and satisfaction. While opioids are the most effective antinociceptive agents, they have undesirable side effects, including respiratory depression, nausea, vomiting, urinary retention, constipation, ileus, and pruritus. Another problem is opioid addiction, a 4.8%-6.5% incidence of persistent opioid use after surgery in older children and adults in the United States [14]. With this mind, opioid-free anesthesia (OFA) was introduced to avoid current crisis. This can be achieved with alpha-2-agonists, ketamine, lidocaine, nonsteroidal anti-inflammatory drugs (NSAIDs) and magnesium, each working on a different target and therefore described as multitarget anesthesia [15]. In hysteroscopy, non-opioid analgesics such as NSAIDs and dexmedetomidine had been evaluated. Although both of these drugs could reduce the pain after hysteroscopy, NSAIDs fail to eliminate the discomfort occurring during the procedure [16] and dexmedetomidine may cause prolonged hypotension and bradycardia [17].
A case report indicated that there is a close connection between hypomagnesaemia and pain. Séamus et al. [18] reported two patients with hypomagnesaemia suffer from severe cancer pain. Their pain was well controlled after treating with intravenous magnesium. During hysteroscopy, distending media is essential to allow for optimal uterine visualization. Nevertheless, excess absorption of large volumes of electrolyte-free, low-viscosity uid can result in volume overload with hyponatremia and water intoxication [19]. In our study, patients’ postoperative serum magnesium level was consistent with recent research [9] which significantly decreased. The use of diuretics is advocated to treat volume overload in hysteroscopy [19], but diuretics can reduce renal magnesium reabsorption. In the meantime, perioperative inadequate dietary intake of magnesium makes patients undergoing hysteroscopy more susceptible to hypomagnesaemia.

Magnesium has antinociceptive effect in animal and human models of pain [20]. As a matter of fact, noxious stimuli activate the release of glutamate in the dorsal horn, which then activates the NMDA receptors, causing intracellular calcium influx, neuronal excitation, and central sensitization and hyperalgesia [21]. Therefore, NMDA receptor antagonists play an important role in perioperative pain control. Furthermore, compared with acute cutaneous pain sensation, NMDA receptor antagonists provide better pain control for acute visceral pain [22]. Thus, we choose magnesium sulphate as a component of multimodal general anesthesia in hysteroscopy.

Less opioid consumption and better analgesia were observed when patients’ magnesium deficiency was corrected. These observations support both the opioid-sparing effect and co-analgesic properties of magnesium. Common causes of hypomagnesemia include diarrhea, alcoholism, acute pancreatitis, uncontrolled diabetes mellitus, and medication such as a proton pump inhibitor and diuretics [23]. Our results indicate that if patients have these risk factors with complex pain, assess and correct magnesium level will be necessary. There is a declining trend for the risk of oxygen desaturation and PONV in the magnesium group, although it did not reach statistically significant. This probably due to short operating time and propofol’s antiemetic effect. Moreover, the recovery of consciousness was not delayed in Group M, while Altan et al. [24] reported that magnesium sulphate caused a delay in recovery for patients undergoing spinal surgery. Magnesium sulphate is known to prolong and potentiate neuromuscular block by non-depolarizing neuromuscular blocking agents [25, 26]. Patients in our study did not receive muscle relaxant and they keep breathe spontaneously. Different surgical model may explain the diverse results on the time of recovery of consciousness between the present study and the result of Altan et al.

Intravenous administration of magnesium generally is associated with minor side effects [7]. Common magnesium-related side effects include flushing, dizziness, and cardiovascular events. Nevertheless, a meta-analysis indicated that magnesium did not have a statistically significant effect on the incidence of dizziness, hypotension, or bradycardia [27]. On the contrary, it was beneficial to reduce postoperative shivering. Hypomagnesaemia can produce numerous symptoms such as pain, weakness, tetany, hallucinations, and arrhythmias [8, 18]. A stable serum magnesium concentration might be helpful for patients’ comfort and postoperative recovery. Jee et al. [28] found that magnesium administration can reduce the release of catecholamine and vasopressin during laparoscopic cholecystectomy. Its
antinociceptive effect and direct vasodilatory effect through a calcium channel blockade might explain the lower HR and MBP in Group M. Although there was no significant difference of hypotension between the two groups in our study, relatively lower MBP might be helpful to reduce intraoperative bleeding and stress response. Even though we did not record the specific reasons for adding bolus doses of fentanyl in our study, less fentanyl consumption can reflect fewer times of body movement. These advantages of magnesium sulphate may create good conditions for operation, shorten the duration of procedure, and eventually improve the satisfaction of gynecologists.

Some limitations of the present study should be noted. First, it was a single-center study, and the relatively small number of patients limited the ability to detect statistically significant differences in adverse events of fentanyl between two groups. Second, we only applied magnesium to multimodal general anesthesia in hysteroscopy. The combination of magnesium with some other medicine in different targets such as lidocaine, ketamine, and dexmedetomidine may be more effective to reduce opioids consumption, even achieve opioid-free anesthesia.

In conclusion, intravenous infusion of magnesium sulphate significantly reduces postoperative pain and perioperative opioids requirements without cardiovascular side effects. Meanwhile, it was beneficial to maintain a stable serum magnesium concentration after the procedure. Thus, we conclude that application of magnesium sulphate is a rational strategy for multimodal general anesthesia in hysteroscopy.

**Abbreviations**

PONV: postoperative nausea and vomiting; BIS: Bispectral Index Scale; ASA: American Society of Anesthesiologists; NIBP: noninvasive blood pressure; SpO2: pulse oximetry; MBP: mean blood pressure; HR: heart rate; PACU: post anesthesia care unit; VNRS: verbal numerical rating scale; OFA: opioid-free anesthesia

**Declarations**

**Ethics approval and consent to participate:** The study was approved by the Ethics Committee of Affiliated Hospital of North Sichuan Medical College [2019ER(R) 074-01] and was registered at the Chinese Clinical Trials Registry (ChiCTR1900024596). Written informed consent was obtained from each patient.

**Consent for publication:** Not applicable
Availability of data and materials: The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: None.

Authors’ contributions: JYL and PFG were responsible for conceived, designed this study and collected the data. SW and YFZ were responsible for study execution and manuscript writing. GQW was responsible for data analysis. QX and XG were responsible interpretation of results and manuscript writing. All authors have read and approved the final version of the manuscript.

Acknowledgments: We thank all the patients, their families, and the institutions for supporting this study.

References


**Tables**

**Table 1.** Demographic characteristics and satisfaction scores between two groups

<table>
<thead>
<tr>
<th></th>
<th>Group C (n=34)</th>
<th>Group M (n=33)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>37.0 ± 8.8</td>
<td>37.3 ± 9.0</td>
<td>0.900</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>52.5 (44-70)</td>
<td>53 (47-65)</td>
<td>0.782</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>157.5 ± 4.3</td>
<td>158.1 ± 4.4</td>
<td>0.575</td>
</tr>
<tr>
<td>BMI(Kg/m²)</td>
<td>22.2 ± 2.5</td>
<td>21.9 ± 2.1</td>
<td>0.618</td>
</tr>
<tr>
<td>ASA Physical status (I/II) (n)</td>
<td>13/21</td>
<td>14/19</td>
<td>0.727</td>
</tr>
<tr>
<td>Duration of procedure (min)</td>
<td>24.7 ± 12.0</td>
<td>20.5 ± 9.7</td>
<td>0.116</td>
</tr>
<tr>
<td>Recovery of consciousness (min)</td>
<td>4.1 ± 0.8</td>
<td>4.0 ± 0.7</td>
<td>0.422</td>
</tr>
<tr>
<td>Satisfaction score from gynecologists</td>
<td>8 (7-10)</td>
<td>9 (8-10) *</td>
<td>0.026</td>
</tr>
<tr>
<td>Satisfaction score from patients</td>
<td>9 (8-10)</td>
<td>10 (8-10)</td>
<td>0.057</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation or median (range).

Group C = control group; Group M = magnesium group.

ASA = American Society of Anesthesiologists.

* The difference was significant at 0.05 level.
### Table 2. Anesthetic requirements and frequencies of perioperative adverse events

<table>
<thead>
<tr>
<th></th>
<th>Group C (n=34)</th>
<th>Group M (n=33)</th>
<th><em>p</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Propofol (mg)</strong></td>
<td>31.2 ± 10.8</td>
<td>28.0 ± 7.0</td>
<td>0.157</td>
</tr>
<tr>
<td><strong>Fentanyl (μg)</strong></td>
<td>145 (75-175)</td>
<td>100 (75-150) *</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Need for rescue analgesics</td>
<td>14 (38%)</td>
<td>6 (21%) *</td>
<td>0.036</td>
</tr>
<tr>
<td><strong>Hypertension (SBP &gt; 150 mmHg)</strong></td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Hypotension (SBP &lt; 90 mmHg)</strong></td>
<td>7 (21%)</td>
<td>5 (15%)</td>
<td>0.562</td>
</tr>
<tr>
<td><strong>Tachycardia (HR &gt; 110 bpm)</strong></td>
<td>2 (6%)</td>
<td>0 (0%)</td>
<td>0.157</td>
</tr>
<tr>
<td><strong>Bradycardia (HR &lt; 50 bpm)</strong></td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory depression</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO₂ &lt; 95%</td>
<td>18 (53%)</td>
<td>12 (36%)</td>
<td>0.172</td>
</tr>
<tr>
<td>SpO₂ &lt; 90%</td>
<td>12 (35%)</td>
<td>7 (21%)</td>
<td>0.201</td>
</tr>
<tr>
<td><strong>PONV</strong></td>
<td>4 (12%)</td>
<td>3 (9%)</td>
<td>0.721</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation, number (proportion) or median (range).  
Group C = control group; Group M = magnesium group.  
PONV = postoperative nausea and vomiting.  
* The difference was significant at 0.05 level.

### Table 3. Postoperative pain profiles during 4 h

<table>
<thead>
<tr>
<th></th>
<th>Group C (n=34)</th>
<th>Group M (n=33)</th>
<th><em>p</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VNRS scores</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 min</td>
<td>2 (0-4)</td>
<td>1 (0-4)</td>
<td>0.074</td>
</tr>
<tr>
<td>15 min</td>
<td>3 (1-6)</td>
<td>2 (1-5) *</td>
<td>0.001</td>
</tr>
<tr>
<td>30 min</td>
<td>3 (2-6)</td>
<td>2 (1-6) *</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1 h</td>
<td>2 (1-5)</td>
<td>1 (0-5) *</td>
<td>0.001</td>
</tr>
<tr>
<td>4 h</td>
<td>2 (1-4)</td>
<td>1 (0-4) *</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>VNRS ≥ 4</strong></td>
<td>14 (38%)</td>
<td>6 (21%) *</td>
<td>0.036</td>
</tr>
</tbody>
</table>

Values are presented as median (range) or number (proportion).  
Group C = control group; Group M = magnesium group.  
VNRS = verbal numerical rating scale.  
* The difference was significant at 0.05 level.
Figure 1

Flow diagram representing patient enrollment, group assignment, and analysis. A total of 70 patients participated in our study without exclusion. They were randomly divided into two groups: the control group (Group C, n=35) and the magnesium group (Group M, n=35). One patient in Group C and two patients in Group M were lost to follow up, thus 34 patients in Group C and 33 patients in Group M were analyzed.
Figure 2

Hemodynamic variables during the procedure. A. Heart rate in the control group (Group C, n=34) and the magnesium group (Group M, n=33) at each point of time. B. Mean blood pressure in the control group (Group C, n=34) and the magnesium group (Group M, n=33) at each point of time.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CONSORT2010ChecklistMSWord.doc